



#8/K.T.
5/14
F.D.S.
EV 032 104 775 US

PATENT

TECH CENTER 1600/2900

MAR 19 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Timothy J. O'Brien, et al.
Serial No. : 09/965,738
Filing Date : September 27, 2001
Title : **Repeat Sequences of the CA125 Gene and Their
Use for Diagnostic and Therapeutic Interventions**
Examiner : Unassigned
Group Art Unit : Unassigned

Assistant Commissioner of Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO/SB/08A. A copy of each of the references listed on the attached form is submitted herewith.

It is respectfully requested that the references listed on the attached form be expressly considered by the Examiner and be made of record in the application and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being submitted prior to the mailing of a first action on the merits in the present application. Accordingly, it is believed that no fees are due for consideration of this Information Disclosure Statement. However, should any fees be due, the Assistant Commissioner is authorized to charge such fees to Deposit Account 16-1435. A duplicate of this sheet is attached for that purpose.

Respectfully submitted,

Date: March 11, 2002

Pat Winston Kennedy
Pat Winston Kennedy
Reg. No. 36,970

KILPATRICK STOCKTON LLP
1001 West Fourth Street
Winston-Salem, North Carolina 27101-2400
(336) 607-7336
(336) 607-7500 Facsimile
Attorney Docket No.: 40715-260477
40715-260477
WINLIB01:936401.1

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	09/965,738
Filing Date	September 27, 2009
First Named Inventor	O'Brien, Timothy J.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	40715-260477
Express Mail Certificate	EV 032 104 775 US

MAR 11 2002

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449APTO


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	09/965,738
Filing Date	September 27, 2001
First Named Inventor	O'Brien, Timothy J.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	40715-260477

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	BAST RC et al., A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, <i>N Engl J Med.</i> 309:883-887 (1983)	✓
	2	BON GC et al., Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference values, <i>Am J Obstet. Gynecol.</i> 174:107-114 (1996)	✓
	3	CLEMONS-MILLER, A et al. Intrathecal Cytotoxic T-Cell Immunotherapy for Metastatic Leptomeningeal Melanoma. <i>Clinical Cancer Research</i> 7:917s-924s, March 2001 (Suppl.)	✓
	4	DESSEYN JL et al., Human mucin gene MUC5B, the 10.7-kb large central exon encodes various alternate subdomains resulting in a super-repeat. Structural evidence for a 11p15.5 gene family, <i>J Biol. Chem.</i> 272(6):3168-3178 (1997)	✓
	5	FENDRICK, JL et al. Characterization of CA 125 Synthesized by the Human Epithelial Amnion WISH Cell Line. <i>Tumor Biol</i> 1993; 14:310-318	✓
	6	FENDRICK, JL et al. CA125 Phosphorylation Is Associated with Its Secretion from the WISH Human Amnion Cell Line. <i>Tumor Biol</i> 1997; 18:278-289	✓
	7	FOON, KA et al., Are solid tumor anti-idotype vaccines ready for prime time?, <i>Clinical Cancer Research</i> 7:1112-1115 (2001)	✓
	8	GENDLER SJ et al., Epithelial mucin genes, <i>Annu. Rev. Physiol.</i> 57:607-634 (1995)	✓
	9	GUM Jr., JR, Mucin genes and the proteins they encode: Structure, diversity and regulation, <i>Am J Respir. Cell Mol. Biol.</i> 7:557-564 (1992)	✓
	10	GUM JR, Human Mucin Glycoproteins: Varied Structures Predict Diverse Properties and Specific Functions. <i>Biochemical Society Transactions.</i> 23(4):795-799, 1995.	✓
	11	HARDARDOTTIR H et al., Distribution of CA125 in embryonic tissue and adult derivatives of the fetal periderm, <i>Am J Obstet. Gynecol.</i> 163;6(1):1925-1931 (1990)	✓
	12	KONISHI I et al., Epidermal growth factor enhances secretion of the ovarian tumor-associated cancer antigen CA125 from the human amnion WISH cell line, <i>J Soc. Gynecol. Invest.</i> 1:89-96 (1994)	✓
	13	LLOYD KO et al., Synthesis and secretion of the ovarian cancer antigen CA125 by the human cancer cell line NIH: OVCAR-3, <i>Tumor Biology</i> 22, 77-82 (2001)	
	14	LLOYD KO et al., Isolation and characterization of ovarian cancer antigen CA125 using a new monoclonal antibody (VK-8): Identification as a ucin-type molecule, <i>Int. J. Cancer</i> , 71:842-850 (1997)	✓
	15	MARSHALL E, DNA Sequencing: Genome teams adjust to shotgun marriage, <i>Science</i> 292:1982-1983 (2001)	✓
	16	NAP M et al., Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2 nd report from the ISOBM TD-1 workshop, <i>Tumor Biology</i> 17:325-331 (1996)	✓
	17	NUSTAD K et al., CA125 - epitopes and molecular size, <i>Int. J of Biolog. Markers</i> , 13(4):196-199 (1998)	✓

Substitute for form 1449APTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	09/965,738
Filing Date	September 27, 2001
First Named Inventor	O'Brien, Timothy J.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	40715-260477

18	NUSTAD K et al., Specificity and affinity of 26 monoclonal antibodies against the CA125 antigen: First report from the ISOBM TD-1 workshop <i>Tumor Biology</i> 17:196-219 (1996)	✓
19	O'BRIEN, TJ et al. CA 125 Antigen in Human Amniotic Fluid and Fetal Membranes. <i>Am J Obstet Gynecol</i> 155:50-55 July, 1986	✓
20	O'BRIEN, TJ et al. New Monoclonal Antibodies Identify the Glycoprotein Carrying the CA 125 Epitope. <i>Am J Obstet Gynecol</i> 1991; 165:1857-64	✓
21	O'BRIEN, TJ et al. More Than 15 Years of CA 125: What Is Known about the Antigen, Its Structure and Its Function. <i>The International Journal of Biological Markers</i> 13:188-195 (1998)	✓
22	QUIRK, JR et al. CA 125 in Tissues and Amniotic Fluid During Pregnancy. <i>Am J Obstet Gynecol</i> 159:655-649 (1988)	✓
23	SANTIN, AD et al. Induction of Ovarian Tumor-Specific CD8+ Cytotoxic T Lymphocytes by Acid-Eluted Peptide-Pulsed Autologous Dendritic Cells. <i>Obstetrics & Gynecology</i> 2000; 96:422-30	✓
24	SANTIN, AD et al. In vitro Induction of Tumor-Specific Human Lymphocyte Antigen Class I-Restricted CD8+ Cytotoxic T Lymphocytes by Ovarian Tumor Antigen-Pulsed Autologous Dendritic Cells from Patients with Advanced Ovarian Cancer. <i>Am J Obstet Gynecol</i> 2000; 183:601-9	✓
25	SHIGESMASA, K, et al. p21: a Monitor of p53 Dysfunction in Ovarian Neoplasia. <i>International Journal of Gynecologic Cancer</i> 7:296-303, 1997.	✓
26	SHIGESMASA, K, et al. p16 Overexpression: A Potential Early Indicator of Transformation in Ovarian Carcinoma. <i>J Soc Gynecol Invest</i> 4:95-102, 1997.	✓
27	VERMA M et al., Mucin genes: Structure, expression and regulation, <i>Glycoconjugate J.</i> 11:172-179 (1994)	✓
27	WAGNER, U. et al. Immunological Responses to the Tumor-Associated Antigen CA125 in Patients with Advanced Ovarian Cancer Induced by the Murine Monoclonal Anti-Idiotypic Vaccine ACA125. <i>HYBRIDOMA</i> 16:33-40 (1997)	✓
29	WAGNER U et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotypic antibody ACA125: Immune responses and survival in palliative treatment, <i>Clin. Cancer Res.</i> 7:1112-1115 (2001)	✓
30	WILLIAMS, SJ et al. MUC13, a Novel Human Cell Surface Mucin Expressed by Epithelial and Hemopoietic Cells. <i>The Journal of Biological Chemistry</i> 276(21):18327-18336, 2001.	✓
31	YIN TWT et al., Molecular cloning of the CA125 ovarian cancer antigen. Identification as a new mucin (MUC16), <i>J Biol. Chem.</i> 276:27371-27375 (2001)	✓
32	ZURAWSKI VR et al., Tissue distribution and characteristics of the CA125 antigen, <i>Cancer Rev.</i> 11-12:102-118 (1998)	✓

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 911366